Tetrahedral framework nucleic acids loaded with baicalein: suppressing oxidative stress and ferroptosis during renal ischemia-reperfusion injury via targeting Sirt1
4 affiliations
- 1Department of Urology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei P. R. China
- 2Institute of Urology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, Hubei P. R. China
- 3Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei P. R. China
- 4Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen, China
Abstract
Renal ischemia-reperfusion (I/R) injury is a major cause of acute kidney injury (AKI), yet effective therapeutic strategies remain scarce. Although the natural flavonoid baicalein possesses potential therapeutic properties, its clinical application is limited by suboptimal pharmacokinetic properties such as poor solubility and low stability. To tackle these challenges, we engineered a nanocarrier system utilizing tetrahedral framework nucleic acids (tFNAs) to enhance the delivery and efficacy of baicalein (tFNA-Bai) against renal I/R injury and to investigate its mechanistic basis. The synthesized tFNA-Bai nanoparticles demonstrated uniform size (~ 20 nm), sustained release kinetics, and significantly improved serum stability and cellular internalization compared to free baicalein. In renal I/R mouse and cell models, tFNA-Bai afforded superior renoprotection, as indicated by more pronounced improvements in renal function, attenuated histological damage, and reduced cellular apoptosis. Mechanistic investigations integrating network pharmacology and experimental validation revealed that the protective effects were linked to the mitigation of oxidative stress and ferroptosis. Further analysis identified Sirtuin 1 (Sirt1) as a direct target of baicalein. Loss-of-function studies in vivo and in vitro confirmed that Sirt1 is an essential mediator for the antioxidant, anti-ferroptotic, and renoprotective actions of baicalein. In summary, this study introduces an efficient DNA nanostructure-based delivery platform that circumvents the pharmacological limitations of baicalein. Our results demonstrate that the enhanced therapeutic efficacy of tFNA-Bai is largely attributed to the activation of the Sirt1 pathway, which substantially inhibits ferroptosis and oxidative stress in renal I/R injury. This approach offers a novel and promising nanotherapeutic strategy for the treatment of I/R-induced AKI.
Graphical abstract:
Related
- Inhibition of PCSK9 protects against myocardial ischemia-reperfusion injury by suppressing ferroptosis via negative regulation of the P65/MMP9 pathway
- Atractylenolide I ameliorates microglia-mediated cerebral ischemia/reperfusion injury by suppressing the TLR4/NF-κB/NLRP3 inflammasome axis
- SGLT2 inhibitors attenuate diabetic kidney disease by suppressing YAP dependent ferroptosis
- CDCA5 promotes hepatocellular carcinoma progression by suppressing ferroptosis through PP2Ac/p53/STEAP3 signaling
- 4-Methoxydalbergione triggers ferroptosis in bladder cancer by suppressing the AKT/mTOR/GPX4 axis
BibTeX
@article{xia2026tetrahedral,
title = {{Tetrahedral framework nucleic acids loaded with baicalein: suppressing oxidative stress and ferroptosis during renal ischemia-reperfusion injury via targeting Sirt1}},
author = {Kang Xia and Qiangmin Qiu and Yunlong Zhang and Yujie Zhou and Daojia Miao and Xiaoping Zhang},
journal = {Journal of Nanobiotechnology},
year = {2026},
month = jul,
doi = {10.1186/s12951-026-04867-4},
url = {https://doi.org/10.1186/s12951-026-04867-4},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Tetrahedral framework nucleic acids loaded with baicalein: suppressing oxidative stress and ferroptosis during renal ischemia-reperfusion injury via targeting Sirt1
AU - Kang Xia
AU - Qiangmin Qiu
AU - Yunlong Zhang
AU - Yujie Zhou
AU - Daojia Miao
AU - Xiaoping Zhang
PY - 2026
DA - 2026/07/29
JO - Journal of Nanobiotechnology
DO - 10.1186/s12951-026-04867-4
UR - https://doi.org/10.1186/s12951-026-04867-4
AB - Renal ischemia-reperfusion (I/R) injury is a major cause of acute kidney injury (AKI), yet effective therapeutic strategies remain scarce. Although the natural flavonoid baicalein possesses potential therapeutic properties, its clinical application is limited by suboptimal pharmacokinetic properties such as poor solubility and low stability. To tackle these challenges, we engineered a nanocarrier system utilizing tetrahedral framework nucleic acids (tFNAs) to enhance the delivery and efficacy of baicalein (tFNA-Bai) against renal I/R injury and to investigate its mechanistic basis. The synthesized tFNA-Bai nanoparticles demonstrated uniform size (~ 20 nm), sustained release kinetics, and significantly improved serum stability and cellular internalization compared to free baicalein. In renal I/R mouse and cell models, tFNA-Bai afforded superior renoprotection, as indicated by more pronounced improvements in renal function, attenuated histological damage, and reduced cellular apoptosis. Mechanistic investigations integrating network pharmacology and experimental validation revealed that the protective effects were linked to the mitigation of oxidative stress and ferroptosis. Further analysis identified Sirtuin 1 (Sirt1) as a direct target of baicalein. Loss-of-function studies in vivo and in vitro confirmed that Sirt1 is an essential mediator for the antioxidant, anti-ferroptotic, and renoprotective actions of baicalein. In summary, this study introduces an efficient DNA nanostructure-based delivery platform that circumvents the pharmacological limitations of baicalein. Our results demonstrate that the enhanced therapeutic efficacy of tFNA-Bai is largely attributed to the activation of the Sirt1 pathway, which substantially inhibits ferroptosis and oxidative stress in renal I/R injury. This approach offers a novel and promising nanotherapeutic strategy for the treatment of I/R-induced AKI. Graphical abstract:
SN - 1477-3155
ER -